Penumbra (NYSE:PEN – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Penumbra to similar businesses based on the strength of its risk, dividends, earnings, institutional ownership, valuation, analyst recommendations and profitability.
Analyst Recommendations
This is a breakdown of recent recommendations for Penumbra and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Penumbra | 0 | 14 | 3 | 0 | 2.18 |
| Penumbra Competitors | 4257 | 10484 | 18211 | 824 | 2.46 |
Penumbra presently has a consensus price target of $367.07, suggesting a potential upside of 14.24%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.11%. Given Penumbra’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Penumbra has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
88.9% of Penumbra shares are owned by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Penumbra and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Penumbra | $1.40 billion | $177.69 million | 80.93 |
| Penumbra Competitors | $1.89 billion | $138.79 million | 10.90 |
Penumbra’s competitors have higher revenue, but lower earnings than Penumbra. Penumbra is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Penumbra has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Penumbra’s competitors have a beta of 2.56, meaning that their average stock price is 156% more volatile than the S&P 500.
Profitability
This table compares Penumbra and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Penumbra | 10.06% | 10.39% | 8.09% |
| Penumbra Competitors | -278.23% | -150.06% | -21.87% |
Summary
Penumbra competitors beat Penumbra on 7 of the 13 factors compared.
About Penumbra
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.
